LDN

What it is

Naltrexone is a pure opioid receptor antagonist — a molecule that binds to opioid receptors and blocks them without activating them. It was approved by the FDA in 1984 for opioid use disorder and in 1995 for alcohol use disorder, at a standard dose of 50 mg/day, where it produces near-complete blockade of mu, kappa, and delta opioid receptors for ~24 hours. That’s the addiction-treatment story most people know.

Low-Dose Naltrexone — LDN — is the same molecule, dosed at 1.5 to 4.5 mg. That’s 3% to 10% of the FDA-approved dose. At this dose range, the molecule does something pharmacologically different: instead of producing sustained opioid receptor blockade, it produces a brief (4–6 hour) partial blockade, which triggers a paradoxical immune-modulatory cascade. It stops being an addiction medication and starts being an immune-system modulator.

The LDN story originated in the mid-1980s with Dr. Bernard Bihari, a New York neurologist who was treating HIV patients in the AIDS-era. He observed that very low doses of naltrexone produced unexpected improvements in his patients’ immune function. He published case series throughout the 1980s and 1990s, and the LDN clinical-practice community has grown from his original work to a network of functional-medicine and integrative-medicine prescribers worldwide, supported by ~20 years of pilot RCTs and a much longer base of clinical-experience data.

The naming convention is worth flagging: “LDN” specifically refers to the 1.5–4.5 mg dose range. “Naltrexone” without the “low-dose” qualifier almost always means the 50 mg addiction-treatment dose. Don’t conflate the two — they are pharmacologically different interventions.

Where you get it: LDN is not commercially manufactured at the 1.5–4.5 mg dose range — every prescription is compounded by a 503A pharmacy from the standard 50 mg naltrexone tablet, into a capsule or liquid suspension at the prescribed dose. This means you need (1) a prescriber willing to write the off-label prescription and (2) a compounding pharmacy. Most functional-medicine practitioners, many telemedicine clinics, and a growing number of conventional MDs will prescribe LDN for accepted indications. It is NOT sold by any peptide vendor (Alyve, AminoClub, BioLongevity) — this is a pharmaceutical compound on the regulated medication side, not the research-chemical side.

How it works

The mechanism has two distinct layers — a systemic-immune layer (the endorphin-rebound mechanism on opioid-receptor-bearing immune cells) and a central-nervous-system layer (TLR4 antagonism on microglia). Both contribute, and the relative weight depends on the indication.

Layer 1 — the endorphin-rebound mechanism (Bihari’s original story)

LDN at the 1.5–4.5 mg dose taken in the evening produces a brief (~4–6 hour) partial blockade of opioid receptors, primarily during overnight hours. The body senses the partial blockade and compensates by upregulating endogenous opioid (endorphin) production — specifically β-endorphin and met-enkephalin. By the time the LDN clears and the receptors are unblocked the next day, circulating endorphin levels are higher than baseline.

Why this matters for immune function: opioid receptors are not limited to the central nervous system. They are also expressed on lymphocytes, macrophages, natural killer cells, and other immune cells throughout the body. β-endorphin and met-enkephalin signaling on these immune cells appears to modulate immune-cell behavior — reducing pro-inflammatory cytokine output (TNF-α, IL-6, IL-1β), restoring NK-cell function, and shifting the immune system away from chronic over-activation toward a more regulated state. The empirical result in patients: reduced systemic inflammation, improved immune-cell coordination, and (in autoimmune patients) reduced attack on self-tissue.

The key word here is modulation, not suppression. Unlike corticosteroids — which globally suppress all immune function and leave patients vulnerable to infection — LDN appears to recalibrate immune balance without dampening necessary defense capacity. This is the same broad “modulation, not suppression” framing that applies to KPV and Thymosin Alpha-1 within the immune-cluster section of the wiki. Three different mechanisms, same editorial principle: support the immune system back toward balance instead of overriding it.

Layer 2 — TLR4 antagonism on microglia (the neuroinflammation mechanism)

The second mechanism, discovered separately and supported by an independent literature base, involves microglia — the resident immune cells of the central nervous system — and Toll-like Receptor 4 (TLR4), an innate-immune receptor that drives microglial inflammation. LDN antagonizes TLR4 on microglia at low doses, blunting neuroinflammation directly. This mechanism, characterized in detail by Hutchinson, Watkins, and colleagues at the University of Adelaide and the University of Colorado, is the main proposed basis for LDN’s effects on:

• Chronic pain syndromes (fibromyalgia, neuropathic pain) — chronic pain has a substantial microglial-inflammation component, and reducing microglial activation reduces central pain sensitization. This is why fibromyalgia responds — it’s neuroinflammation, not peripheral tissue damage, driving the pain.
• Brain fog + cognitive symptoms in autoimmune patients, long COVID, and chronic fatigue conditions. Microglial activation contributes to the “sickness behavior” cluster (fatigue, low motivation, cognitive sluggishness, anhedonia). Calming microglia recovers cognitive bandwidth.
• Multiple sclerosis — both for symptomatic management and as a possible disease-modifying signal in some early trials.

The TLR4 mechanism operates at the lower end of the LDN dose range and is functionally independent of the opioid-receptor mechanism. Some practitioners interpret this as evidence that lower LDN doses (1.5–3 mg) preferentially target the neuroinflammation side, while higher doses (3–4.5 mg) recruit more of the endorphin-rebound systemic-immune mechanism. The dose-response biology is complex and not fully characterized; in practice, titration to the dose that produces the response is empirical.

How LDN slots into the autoimmune-on-GLP-1 patient — the specific mechanism that makes it the missing layer

For the OHM customer profile this article is built around — the autoimmune patient stalled on a GLP-1 receptor agonist — the mechanism story is mechanistically clean:

1. Chronic autoimmune inflammation produces elevated TNF-α, IL-6, and IL-1β circulating in plasma.
2. These inflammatory cytokines impair insulin signaling at the cellular level by activating intracellular kinases (JNK and IKKβ) that phosphorylate IRS-1 on serine residues, blocking the normal tyrosine-phosphorylation cascade insulin needs to move glucose into cells. The cell becomes insulin-resistant from the inside while the receptors at the surface still function normally. [established metabolic-inflammation literature]
3. Insulin resistance → elevated insulin → fat-storage mode (insulin suppresses lipolysis).
4. GLP-1 receptor agonists have modest anti-inflammatory effects (well-documented in the cardiovascular and renal-outcome literature for Semaglutide and Tirzepatide) but they were not designed to handle severe immune dysregulation. When the inflammatory load exceeds what GLP-1’s modest immune-modulation can handle, metabolic improvement is insufficient.
5. LDN reduces the inflammatory cytokine output at the source (immune-modulation layer) and calms microglial neuroinflammation (TLR4 layer) → restoring insulin signaling → unlocking fat oxidation → the GLP-1 starts working the way it would have if the inflammatory load weren’t there.

This is why some practitioners describe LDN as “the bridge between symptom management and metabolic healing” for this patient profile — the metaphor isn’t accidental. LDN doesn’t replace the GLP-1; it removes the inflammatory ceiling that was preventing the GLP-1 from delivering its full effect. The two work the same metabolic problem from opposite angles.

What the research shows

LDN’s evidence base is substantially deeper than most “alternative” interventions but shallower than mainstream prescription drugs — a pattern characteristic of off-label generic compounds where there is no patentable product to attract pharma RCT funding. Per OHM’s evidence-asymmetry rule (umbrella doctrine §2), the absence of large-scale industry-funded Phase III RCTs is a gap, not a refutation — it reflects funding economics, not biology. The actual evidence base is robust enough that LDN is widely prescribed off-label by mainstream rheumatologists, gastroenterologists, neurologists, and functional-medicine physicians.

Fibromyalgia — the strongest LDN human evidence base

• Younger J, Mackey S. 2009. Pain Medicine. [pilot, N=10] — first prospective LDN trial in fibromyalgia. Significant pain reduction vs placebo phase.
• Younger J, Noor N, McCue R, Mackey S. 2013. Arthritis & Rheumatism. [pilot RCT, N=31, PMID 23359310] — LDN reduced fibromyalgia pain ~28.8% vs placebo, no significant adverse events. ✅ verified.
• 2023 Biomedicines trial — additional fibromyalgia trial reporting substantial pain relief in a subset of patients.
• Multiple subsequent observational studies + clinic series. Net effect: fibromyalgia is the strongest LDN-supported indication, and many U.S. and European pain clinics now consider LDN a first-line option for fibromyalgia patients who haven’t responded to standard care.

Crohn’s disease / Inflammatory Bowel Disease

• Smith JP, Stock H, Bingaman S, et al. 2007. American Journal of Gastroenterology. [pilot, open-label, N=17, PMID 17222320] — LDN 4.5 mg/day for 12 weeks in moderate-to-severe Crohn’s. 89% clinical response, 67% remission. Among the strongest pilot data in the LDN literature. ✅ verified.
• Smith JP, Bingaman SI, Ruggiero F, et al. 2011. Digestive Diseases and Sciences. [pilot RCT, N=18, PMID 21336996] — placebo-controlled follow-up confirming improvement signal. ✅ verified.
• Pediatric Crohn’s open-label pilot (Smith 2013).
• LDN is now in NICE-style guideline discussion in some European jurisdictions for IBD; broadly used off-label in the U.S. by gastroenterologists familiar with the data.

Multiple Sclerosis

• Cree BA, Kornyeyeva E, Goodin DS. 2010. Annals of Neurology. [pilot RCT, N=80] — LDN 4.5 mg/day for 8 weeks; improvement in quality-of-life measures in MS patients. ✅ verified.
• Sharafaddinzadeh N, Moghtaderi A, Kashipazha D, et al. 2010. Multiple Sclerosis Journal. [pilot RCT] — similar quality-of-life signal.
• Gironi M, Martinelli-Boneschi F, et al. 2008. Multiple Sclerosis Journal. [pilot, N=40] — safety + tolerability in MS confirmed.
• Net assessment: LDN is not approved as MS disease-modifying therapy and OHM does NOT position it that way. It’s used as adjunctive symptom management (fatigue, spasticity, pain, brain fog) alongside the patient’s standard disease-modifying treatment.

Other autoimmune / chronic inflammatory conditions

• Hashimoto’s thyroiditis: no published RCT to date. Multiple observational clinic series report improved thyroid antibody profiles, reduced TSH variability, and improved fatigue/cognitive symptoms in LDN-treated Hashimoto’s patients.
• Lupus / Rheumatoid Arthritis: small open-label series + clinic-experience base. Used as adjunct to standard disease-modifying therapy.
• Psoriasis: case series + reported symptomatic improvement.
• Long COVID / post-viral fatigue syndrome: growing evidence base. Recent International Immunopharmacology trial reported improvements in fatigue, brain fog, and sleep. The TLR4-microglia mechanism aligns mechanistically with the neuroinflammation hypothesis of post-viral fatigue.
• Complex Regional Pain Syndrome (CRPS): case series + emerging interest.

Cancer-supportive use (Bihari’s original interest)

• LDN has a long observational case-series history in cancer-supportive care, originating with Bihari’s HIV-era work. OHM does not position LDN as a cancer therapy — the human-trial evidence base for cancer is weak, the mechanism for cancer is speculative, and that’s not the use case OHM is built around. Capture for completeness, do not promote.

The cytokine / inflammatory marker direct evidence

• Multiple studies have shown LDN reduces circulating inflammatory cytokines (TNF-α, IL-6, IL-12, IFN-γ) in autoimmune patients over 4–12 week periods.
• CRP and ESR drops in LDN-treated autoimmune patients are clinically observed widely in functional-medicine and rheumatology practice. The magnitude varies by patient and underlying condition.

The honest tier summary

• ** evidence:** strong for fibromyalgia, moderate for Crohn’s, moderate-emerging for MS, emerging for long COVID. Most trials are small (N=10–80), single-center, and not industry-funded. The pattern is directionally consistent and biologically plausible, not yet supported by mega-trial-scale Phase III data.
• : strong across Hashimoto’s, lupus, RA, psoriasis, IBS, chronic fatigue. ~20 years of practitioner experience with reproducible patterns.
• The mechanistic biology (endorphin rebound + TLR4 antagonism on microglia) is well-characterized in preclinical and translational literature.

Real-world protocol

The doses and recommendations here are for educational and informational purposes only. LDN requires a prescription from a licensed practitioner and is compounded by a 503A pharmacy. This is not medical advice. Consult a qualified physician before beginning LDN, especially if you take any opioid-containing medication, have a history of substance use disorder, are pregnant, or have liver disease.

Standard titration

The clinical convention across most LDN-prescribing practitioners:

Week	Dose	Notes
Weeks 1–2	1.5 mg nightly, ~30 min before bed	Initial dose; tolerability check. Common early-titration signal: vivid dreams.
Weeks 3–4	3 mg nightly	If 1.5 mg tolerated. Some patients plateau here.
Weeks 5–6	4.5 mg nightly	Target therapeutic dose for most indications.
Weeks 7+	Hold at effective dose	Re-evaluate at 8–12 weeks. Adjust based on clinical response + inflammatory markers (CRP, ESR).

Some patients respond best at 3 mg and don’t tolerate 4.5 mg well (insomnia, vivid dreams persisting). Some respond best at 4.5 mg and don’t see effect at 3 mg. A subset of fibromyalgia patients respond at 1.5 mg and don’t benefit from higher doses (consistent with the TLR4-microglia mechanism being most active at the low end). Titration is empirical — find the dose that produces the response and hold it.

Timing

• Evening dose, ~30 min before bed. This is the consensus protocol. The mechanism requires the 4–6 hour opioid-receptor blockade window to occur during sleep, when endogenous endorphin production cycles peak.
• If insomnia develops during titration, some practitioners move the dose to morning (which sacrifices some of the timing-based mechanism but maintains the steady-state effect). The morning-dose option is a backup, not the default.

How long to stay on it

• Long-term, continuous use is the norm. LDN is not cycled. There is no clinical convention for “cycling off.” Most patients on LDN for autoimmune conditions stay on it indefinitely at the effective dose, with periodic re-evaluation of need.
• Some patients on combined LDN + GLP-1 + dietary protocols see autoimmune symptoms enter sustained remission and discuss with their prescriber whether to taper LDN. This is highly individual and depends on inflammatory-marker trajectories.
• If you do choose to stop: simply discontinue. There is no withdrawal syndrome at LDN doses (because there is no opioid-receptor agonism to withdraw from). Symptoms may gradually return over weeks-to-months if inflammation drives the underlying condition.

What to track on LDN

• Inflammatory markers: CRP (high-sensitivity preferred), ESR, ferritin (an inflammation acute-phase reactant when elevated alongside CRP).
• For autoimmune-specific patients: condition-specific antibody panels (TPO/TgAb for Hashimoto’s, anti-CCP for RA, ANA for lupus, etc.).
• Metabolic markers (especially if you’re on a GLP-1): fasting insulin, HbA1c, fasting glucose, lipid panel.
• Symptom diary: subjective pain, energy, brain fog, sleep quality — these often improve before lab markers do.

Safety, side effects, and the critical contraindication

The hard contraindication

Do not take LDN if you are taking any opioid medication. This includes prescription opioids (morphine, oxycodone, hydrocodone, tramadol, codeine, buprenorphine), some opioid-containing cough medicines, and some compounded formulations. LDN — even at low doses — will precipitate acute opioid withdrawal in opioid-dependent patients. This is the single most important safety rule.

Practical implication: if you take any opioid for chronic pain, you cannot start LDN until you have transitioned off opioids and waited the prescriber-recommended washout period (typically 7–10 days minimum). This is a conversation with your prescribing physician.

Common side effects (mostly during titration)

• Vivid dreams — the most universal LDN signal. Typically peaks during weeks 1–3, often diminishes thereafter. Some patients find the dreams interesting; some find them disruptive.
• Insomnia or sleep disruption — moderately common. Often resolves with continued titration; some patients respond to moving the dose to morning.
• Mild GI upset — uncommon, usually transient.
• Headache — uncommon, usually transient during titration.
• Increased fatigue during the first week — uncommon, usually transient.

What’s NOT a concern at LDN doses

• Liver toxicity. Full-dose (50 mg) naltrexone carries a boxed warning for hepatotoxicity at very high doses (300+ mg). At LDN doses (1.5–4.5 mg, 3–10% of the FDA-approved dose), hepatotoxicity has not been observed. Patients with active liver disease should still discuss with their prescriber, but routine liver-function monitoring is not standard for LDN.
• Dependence / addiction. Naltrexone has zero abuse potential — it is a pure antagonist, not an agonist. You cannot get “high” on naltrexone. There is no withdrawal syndrome on discontinuation.
• Immune suppression. LDN is an immune modulator, not an immune suppressant — it does not increase infection risk the way corticosteroids or biologics do.

Pregnancy / breastfeeding

LDN safety in pregnancy and breastfeeding is not well-characterized. Most prescribers stop LDN during pregnancy as a precaution; some specialists continue it in autoimmune patients where flare risk would outweigh theoretical concerns. This is a specialist conversation, not a general recommendation.

Drug interactions worth flagging

• Any opioid medication — see hard contraindication above.
• Methadone or buprenorphine — absolute contraindication. LDN will precipitate severe withdrawal.
• Tramadol — partial opioid agonist; same contraindication.
• Some antidiarrheal medications (loperamide / Imodium) at high doses can act on opioid receptors; LDN may reduce their effect.
• General anesthesia / surgical opioids — discontinue LDN 24–72 hours before scheduled surgery (per surgeon and anesthesiologist guidance). This is to prevent reduced opioid analgesia during surgery. Resume after the perioperative opioid window closes.

What about combining with other immune modulators?

• LDN + biologics (Humira, Enbrel, Remicade, etc.) for autoimmune conditions: clinical practice is generally favorable — LDN is often added to a biologic to improve symptom control. Some patients on the combination see better response than on either alone. Specialist supervision recommended.
• LDN + traditional DMARDs (methotrexate, sulfasalazine, hydroxychloroquine): widely combined in practice with good tolerability.
• LDN + GLP-1 receptor agonists (Semaglutide / Tirzepatide / Retatrutide): this is the OHM-headline use case. No known pharmacokinetic interaction. The pharmacology is complementary — different mechanisms, different targets, additive clinical effect.
• LDN + BPC-157 / KPV / Thymosin Alpha-1: no known interaction. The combination is the full autoimmune-on-GLP-1 stack described below.

Where LDN fits in OHM stacks

The autoimmune-on-GLP-1 plateau stack (the headline use case)

For the OHM customer profile this article is built around — an autoimmune patient (Hashimoto’s, IBD, RA, MS, lupus, psoriasis) who is on a Semaglutide / Tirzepatide / Retatrutide protocol and stalled — the stack:

Layer	Compound	Role	Timing
1. Foundation	GLP-1 receptor agonist (current Rx)	Metabolic foundation + modest immune-modulation	Continue at the prescriber-established dose
2. Immune modulation	LDN 1.5 → 4.5 mg evening	Reduces inflammatory cytokine output, calms microglial neuroinflammation, restores immune balance	Start immediately. Titrate over 4–8 weeks.
3. Anti-inflammatory dietary intervention	Therapeutic elimination diet (carnivore is one option; AIP / strict Whole30 are others)	Removes plant-defense compound triggers, collapses insulin spikes, supports gut healing	Start alongside LDN. 3-month therapeutic protocol, then systematic reintroduction.
4. Gut-barrier layer (weeks 4–8 if needed)	BPC-157 oral 500 µg/day + KPV (both available together in KLOW)	Restores tight-junction proteins (BPC-157); suppresses NF-κB in colonic cells (KPV); closes the leaky-gut → LPS → systemic-inflammation circuit	Add when persistent gut symptoms remain after initial LDN response
5. Advanced immune retraining (weeks 8–12 if severe / multi-condition)	Thymosin Alpha-1	Modulates T-cell function, reduces autoimmune aggression without globally suppressing necessary immune function	Add for patients with severe presentations or multiple concurrent autoimmune conditions

The LDN vs Thymosin Alpha-1 distinction is worth understanding, because both are immune modulators and the question “do I need both?” comes up: LDN calms the inflammatory storm; TA1 retrains the immune system. Different jobs. LDN reduces active cytokine output and dampens microglial-driven neuroinflammation in the short-to-medium term. TA1 modulates T-cell function and reduces autoimmune aggression in a deeper, slower-acting way. Together they create comprehensive immune balance for severe or multi-condition autoimmune patients. Not redundant.

The fibromyalgia stack

For fibromyalgia patients (which is technically a chronic-pain / neuroinflammation condition rather than a classical autoimmune condition):

• LDN 1.5–4.5 mg evening (the headline intervention — fibromyalgia is the indication with the strongest LDN-specific trial data).
• Sleep optimization — sleep deprivation amplifies central pain sensitization, undoing LDN’s effect.
• Magnesium glycinate at bedtime — common adjunct; helps sleep + mild central effect.
• Resistance training titrated to capacity — fibromyalgia patients often improve on graded exposure to load; LDN reduces the inflammatory ceiling that’s blocking exercise tolerance.

The MS / neuroinflammation symptom-management stack

For MS patients (used adjunctively to standard disease-modifying therapy — LDN is NOT a substitute for MS DMT):

• LDN 4.5 mg evening — for fatigue, spasticity, pain, brain fog.
• Continue prescriber-managed disease-modifying therapy.
• Vitamin D 5000+ IU/day (background MS-relevant intervention; verify level via labs).
• NAD+ / mitochondrial support stack (see NAD+, MOTS-c, SS-31 (Elamipretide)) for the cellular-energy / fatigue dimension.

The long COVID stack (emerging use case)

For patients with post-viral fatigue / brain fog / “long COVID” presentations:

• LDN 1.5–4.5 mg evening — targets the microglial neuroinflammation component.
• NAD+ injectable or sublingual — addresses the cellular-energy deficit common in post-viral states.
• SS-31 (Elamipretide) for severe mitochondrial-fatigue cases (research-chem peptide; advanced layer).
• Anti-inflammatory dietary protocol matched to the patient’s triggers.

Where LDN does NOT fit (honest limits)

OHM’s voice is empowerment-with-honest-limits. LDN is not a universal answer.

• LDN is not a weight-loss drug. Patients on LDN for autoimmune conditions often experience weight-loss “unblock” as a downstream effect of reduced inflammation + restored insulin signaling, but LDN alone is not weight-loss therapy. The headline OHM use case is autoimmune-driven inflammation blocking the GLP-1’s effect — the GLP-1 is the weight-loss intervention; LDN removes the inflammatory ceiling.
• LDN is not for opioid-dependent patients until they’ve completed an opioid washout. See safety section.
• LDN is not a substitute for disease-modifying therapy in MS, RA, IBD, lupus, or any other condition where DMT is prescribed. It’s an adjunct, not a replacement.
• LDN has no documented use case in the muscle / GH / longevity peptide stacks (Sermorelin, Ipamorelin, MOTS-c, GHK-Cu, BPC-157 for orthopedic indications). It belongs specifically in the immune-inflammation lane.
• LDN is not a research chemical — do not source it from peptide vendors. It is a regulated pharmaceutical compound requiring a prescription.

How to access LDN

The practical path:

1. Find a prescriber. Functional-medicine clinics, integrative-medicine practitioners, telemedicine platforms specializing in autoimmune or chronic-pain care, and a growing number of conventional rheumatologists, gastroenterologists, neurologists, and pain-management physicians will prescribe LDN. The LDN Research Trust maintains a public prescriber directory.
2. Get the prescription written for the compounded dose. Most prescribers will write for 1.5 mg, 3 mg, and 4.5 mg capsules (or a liquid suspension for fine titration) — verifying the titration schedule with the patient. The script specifies a 503A compounding pharmacy.
3. Fill at a compounding pharmacy. Major LDN-experienced compounding pharmacies will ship nationally; many can fill in 1–3 days. Insurance typically does not cover compounded LDN; expect $30–50/month out-of-pocket for the compounded supply.
4. Establish a follow-up cadence. Most prescribers recommend a 6–12 week follow-up after starting LDN to evaluate response, adjust dose if needed, and check inflammatory markers.

OHM does not currently route LDN customers to any specific clinic or pharmacy — this is education and clinic-routing content with no direct affiliate revenue. ([FUTURE-MONETIZATION] if a clinic affiliate relationship makes sense later.) The actionable framing for the reader: “if you have an autoimmune condition and you’re stalled on a GLP-1, ask your prescriber about LDN. If they don’t prescribe it, the LDN Research Trust prescriber directory is the entry point.”

The honest comparison: LDN vs the alternatives

For autoimmune patients on GLP-1s who are stalled, the other things they might be considering or have been offered:

Intervention	Mechanism	Where it fits	Notes
LDN	Endorphin rebound + TLR4 antagonism on microglia → immune modulation	The headline OHM recommendation for this profile	Low cost, oral, generally well-tolerated, decades of safety record
Biologics (Humira / Enbrel / Remicade / Stelara)	Block specific cytokines (TNF-α, IL-12/23, etc.)	Standard care for moderate-to-severe autoimmune conditions; very effective for severe presentations	Expensive ($30K-100K/year retail), require injection, carry infection risk, immunosuppressive
Methotrexate / hydroxychloroquine / sulfasalazine (DMARDs)	Various anti-inflammatory / immune-modulatory mechanisms	Standard care for RA, lupus, etc.	Long track record; require monitoring; can have meaningful side effects
Corticosteroids (prednisone)	Global immune suppression via glucocorticoid receptor	Acute flare management	Catastrophic as long-term therapy; metabolic + bone + infection costs add up fast
NSAIDs	COX inhibition → reduced prostaglandin output	Symptomatic only	Don’t address autoimmune mechanism; GI/CV/renal risk with chronic use
Functional-medicine elimination diets (carnivore, AIP, strict paleo)	Remove dietary triggers, support gut healing	Adjunct to LDN + standard care	High individual variability; carnivore is a 3-month therapeutic protocol, not a permanent diet for most patients

The OHM editorial position: LDN is consistently the most under-utilized intervention for this profile. It’s cheap, oral, well-tolerated, and addresses a mechanism (chronic-inflammation-driven insulin resistance) that the standard GLP-1 protocol doesn’t fully solve. It’s adjunct to — not replacement for — standard care.

Cross-references in the wiki

• BPC-157 — gut-barrier layer of the autoimmune-on-GLP-1 stack; oral 500 µg/day protocol pairs with LDN.
• KPV — NF-κB-suppressing tripeptide; same gut-barrier layer; available in KLOW alongside BPC-157.
• KLOW — the Alyve blend (BPC-157 + TB-500 + KPV + GHK-Cu); the natural injectable adjunct for autoimmune patients adding gut-barrier work to LDN + GLP-1.
• Thymosin Alpha-1 — advanced-layer immune modulator; “retrains” the immune system where LDN “calms the storm”; weeks 8–12 layer for severe or multi-condition autoimmune cases.
• Semaglutide, Tirzepatide, Retatrutide — the GLP-1 foundation layer; LDN bridges the gap when autoimmune inflammation blocks the GLP-1’s effect.
• SS-31 (Elamipretide), MOTS-c, NAD+ — adjacent cellular-energy stack for post-viral fatigue + brain-fog presentations; LDN handles the inflammation side, these handle the mitochondrial-energy side.
• Immune cluster — LL-37, KPV, VIP (the anti-inflammatory / antimicrobial trio) — broader immune-modulation peptide cluster; LDN sits alongside as a non-peptide adjunct.

---

Last updated: 2026-06-18. Article created under Doctrine #1 (scope expansion: peptides KB covers peptide compounds AND adjunct supplements/pharmaceuticals/nutrition/lifestyle that materially affect peptide outcomes). LDN is a prescription pharmaceutical, not a peptide; it lives in the peptides branch only until a dedicated supplements/ or pharmaceutical-adjuncts/ branch exists. Primary source:. Verified against the broader LDN literature: Younger 2013/2014, Toljan & Vrooman 2018, Smith 2007/2011, Cree 2010, Brown & Panksepp 2009. Doctrine #3 applied throughout — no verbatim quotes attributed to practitioners; everything in OHM voice.